Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Information source: Allergopharma GmbH & Co. KG
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergy; Rhinitis; Conjunctivitis
Intervention: Allerslit forte (Biological); Allerslit forte (Biological)
Phase: Phase 3
Status: Completed
Sponsored by: Allergopharma GmbH & Co. KG Official(s) and/or principal investigator(s): Kristian Reich, Professor, Principal Investigator, Affiliation: not affiliated
Summary
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
Clinical Details
Official title: A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Symptom and Medication Score
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Allergic rhinoconjunctivitis attributable to grass pollen
- Positive SPT
- Positive EAST
- Positive provocation Test
Exclusion Criteria:
- Serious chronic disease
- other perennial allergies
Locations and Contacts
Prof. Kristian Reich, MD, Hamburg 20354, Germany
Additional Information
Leader in specific allergy research and therapy Click here for information about this trial in the European Clinical Trials Register
Starting date: March 2008
Last updated: November 7, 2013
|